|
J Biol Chem, Vol. 274, Issue 42, 29763-29771, October 15, 1999
The Procyclin Repertoire of Trypanosoma brucei
IDENTIFICATION AND STRUCTURAL CHARACTERIZATION OF THE
GLU-PRO-RICH POLYPEPTIDES*
Alvaro
Acosta-Serrano §,
Robert N.
Cole ¶,
Angela
Mehlert ,
Mary G.-S.
Lee** ,
Michael A. J.
Ferguson , and
Paul T.
Englund
From the Department of Biological Chemistry, Johns
Hopkins University School of Medicine, Baltimore, Maryland 21205, the
Department of Biochemistry, University of Dundee, Dundee DD1
5EH, Scotland, United Kingdom, and the ** Department of Pathology,
New York University School of Medicine,
New York, New York 10016
 |
ABSTRACT |
The surface of the insect stages of the protozoan
parasite Trypanosoma brucei is covered by abundant glycosyl
phosphatidylinositol (GPI)-anchored glycoproteins known as procyclins.
One type of procyclin, the EP isoform, is predicted to have 22-30
Glu-Pro (EP) repeats in its C-terminal domain and is encoded by
multiple genes. Because of the similarity of the EP isoform sequences
and the heterogeneity of their GPI anchors, it has been impossible to
separate and characterize these polypeptides by standard protein fractionation techniques. To facilitate their structural and functional characterization, we used a combination of matrix-assisted laser desorption ionization and electrospray mass spectrometry to analyze the
entire procyclin repertoire expressed on the trypanosome cell. This
analysis, which required removal of the GPI anchors by aqueous hydrofluoric acid treatment and cleavage at aspartate-proline bonds by
mild acid hydrolysis, provided precise information about the
glycosylation state and the number of Glu-Pro repeats in these proteins. Using this methodology we detected in a T. brucei
clone the glycosylated products of the EP3 gene and two
different products of the EP1 gene (EP1-1 and EP1-2).
Furthermore, only low amounts of the nonglycosylated products of the
GPEET and EP2 genes were detected. Because all
procyclin genes are transcribed polycistronically, the latter finding
indicates that the expression of the GPEET and
EP2 genes is post-transcriptionaly regulated. This is the first time that the whole procyclin repertoire from procyclic trypanosomes has been characterized at the protein level.
 |
INTRODUCTION |
African trypanosomes are protozoan parasites responsible for
sleeping sickness in humans and the disease nagana in livestock. Trypanosomes alternate between the invertebrate vector
(Glossina, or tsetse fly) and the mammalian host, and the
different life cycle stages are uniquely adapted to survive in each
host. In the mammalian bloodstream form of the parasite,
107 identical variant surface glycoprotein
(VSG)1 molecules are
expressed on the plasma membrane, forming a dense coat. The parasite
can survive the immune attack of its host because it undergoes
antigenic variation, a process in which its surface coat is replaced by
another composed of an antigenically different VSG molecule (1, 2).
When the trypanosome is ingested by the tsetse fly and differentiates
into a procylic form, the VSG coat is totally replaced by one composed
of an array of different proteins, known as procyclins
(3-5).2
The Trypanosoma brucei procyclins, present in about 2.2 × 106 copies/cell, have very unusual structures, with the
C-terminal domain consisting of amino acid repeats. One set of
proteins, the EP isoforms, is predicted to contain between 22-30
Glu-Pro (EP) repeats, whereas the GPEET form, in contrast, has six
Gly-Pro-Glu-Glu-Thr (GPEET) repeats followed by three EP repeats (see
Fig. 1A for a schematic
diagram of procyclin structures and Fig. 1B for their amino
acid sequences). Unlike VSG, procyclin is encoded by a small number of
different genes, and therefore it has only a limited potential for
variation. In the T. brucei 427 strain, the EP isoforms are
encoded by the EP1 (4, 6-8), EP2 (10), and
EP3 (5, 9) genes, whereas GPEET-procyclin is the product of
the GPEET gene (11). All procyclin genes are contained in
four expression sites (per diploid genome), and each site contains two
procyclin genes in a tandem array (see map in Fig. 1C).
Transcription of these genes is polycistronic and can occur
simultaneously from two or more expression sites (reviewed in Ref.
12).

View larger version (35K):
[in this window]
[in a new window]
|
Fig. 1.
Procyclin structure and gene
organization. A, schematic representation of both EP-
and GPEET-procyclin structures. EP-procyclin polypeptides contain a
variable number of Glu-Pro repeats in the C-terminal domain.
EP-procyclin products of the EP1 and EP3 genes
are glycosylated at Asn29 and contain an Asp-Pro-Asp-Pro
sequence that is sensitive to cleavage by mild acid (28). The
EP2 product contains neither a glycosylation site nor
Asp-Pro bonds (10). GPEET-procyclin, the product of the
GPEET gene, has no site for N-glycosylation and
contains six GPEET repeats (11). This molecule is extensively
phosphorylated at threonines in the repeats (18, 19). B,
predicted amino acid sequences of the products of the EP-procyclin
genes (EP1-1, EP1-2, EP3, and
EP2) (5-10) and the GPEET-procyclin gene (GPEET)
(11). Another EP1 gene product predicted to contain 29 EP
repeats and Gly at position 24 has been reported from another strain
(4), but it was not detected in this study. For simplicity, only the
sequence of mature proteins (without signal peptides and GPI addition
signals) are shown; sequence numbering starts at the N terminus of the
mature protein (i.e. Ala1). Underlined
letters represent sites for N-glycosylation
(Asn29). 10 and 4 with
brackets indicate the N-terminal sequences missing in some
of the species identified by MALDI-TOF-MS (Figs. 2A and 6).
C, simplified diagram of procyclin loci in T. brucei 427 strain. Loci names are at left. All genes
are allelic, and the products of the EP1-1 and
EP1-2 genes differ in sequence (see text). This model is not
drawn to scale and shows only the pair of procyclin genes present in
each locus. The EP1-1, EP1-2, EP2,
EP3, and GPEET genes were formerly called
B2 , B1 , B , A , and A
respectively (see new nomenclature in Ref. 37). A more detailed map of
procyclin expression sites is shown elsewhere (12, 37).
|
|
There are other important structural features of the procyclin proteins
(Fig. 1A). Some EP forms can be N-glycosylated
with the products of the EP1 and EP3 genes, but
not that of the EP2 gene, containing a site for
N-glycan addition (i.e. Asn29; Fig.
1B). GPEET-procyclin also has no N-glycosylation
site. The N-glycan is Man5GlcNAc2,
and it is unusual in that it does not exhibit microheterogeneity (13,
14). In addition, all of the procyclin proteins have GPI anchors of
unusual structure, characterized by a very large (average of 30 sugar
residues), heterogeneous branched poly-N-acetyllactosamine
side chain (13, 15). This side chain serves as the sialic acid acceptor
for the cell surface trans-sialidase (16, 17). The anchors
on EP- and GPEET-procyclin are similar or identical in structure (13).
Additionally, GPEET-procyclin is modified by phosphorylation on six out
of seven threonine residues in the repeat sequence (18-20), but this
modification has not been reported for the EP forms.
The function of any of the procyclins is still unclear, although
recently it was demonstrated that mutant parasites that express no EP
isoforms cannot establish heavy infections in tsetse fly midguts (21).
Furthermore, the wild type phenotype was partially rescued after
overexpression of either nonglycosylated or glycosylated EP isoforms
(21). Interestingly, both EP- and GPEET-procyclin are co-expressed on
the parasite surface, although their ratio varies in different clones.
When some of these clones are maintained in culture for several months,
there is a shift in expression, from EP- to GPEET-procyclin, ending
with cells containing low levels of EP proteins (13, 18).
In elucidating the function of procyclin molecules, it is of great
interest to determine whether all of the different EP-procyclin genes
are expressed as proteins and to determine the relative levels of
expression. It is also important to establish whether this expression
varies with time or under different experimental conditions. Such
variation could have considerable biological relevance. For example, a
programmed variation of procyclin expression could control the behavior
of the parasite in its insect vector. Although the EP and GPEET forms
can be detected by monoclonal antibodies (20), to date it has not been
possible to analyze or resolve the protein products of the different
EP-procyclin genes, because of their very similar amino acid sequences
(Fig. 1B) in addition to the extreme heterogeneity in their
GPI anchor.
In this paper, we report a complete characterization of the
EP-procyclin repertoire by mass spectrometry, revealing most of the
species predicted from gene sequences. To apply this technique, it was
necessary to remove the GPI anchor by treatment with aqueous hydrofluoric acid (aq.HF), a well characterized method that has a
minimal effect on the polypeptide chain and glycosidic bonds. This
method was previously used in a mass spectrometric analysis of the
phosphorylation of purified GPEET-procyclin (19). However, to fully
characterize these molecules it was also essential to develop a new
method involving mild acid hydrolysis that selectively cleaves the
EP1 and EP3 (but not EP2) gene
products at Asp-Pro sequences. Using this methodology, we were able to
identify by mass spectrometry all of the procyclin polypeptides present
in a T. brucei 427 strain as well as to obtain new
information on procyclin expression. Furthermore, for each of the EP
isoforms, we determined an accurate molecular mass, the extent of
glycosylation, and the exact number of EP repeats.
 |
EXPERIMENTAL PROCEDURES |
Parasites--
The wild type procyclic T. brucei
brucei 427 clone had been stored at New York University in the
laboratory of M. G.-S. Lee. This cell line was originally obtained
in 1988 by in vitro differentiation of T. b.brucei 118 bloodstream clone 1 (6). The parasites had been
cultured as procyclic cells for a total of about 6 weeks (since
differentiation) before procyclin was isolated for the experiments
described in Figs. 2-5. Ten cloned lines from the original 1988 clone
were obtained at New York University by stably transforming the 1988 clone with the same DNA construct (H23H-B7) and using hygromycin as a
selectable marker (22). The H23-H-B7 construct contains the
hsp70 intergenic region promoter followed by the hph gene, the  -tubulin intergenic region, and a
targeting sequence derived from the VSG 118 expression site (22). The
transformed parasites were cloned by limiting dilution in the presence
of trypanosomes not resistant to the drug. Another cloned line (clone 6) was obtained at Johns Hopkins University from the same T. brucei 1988 strain by limiting dilution in conditioned medium.
Parasites were grown at 27 °C in SDM-79 medium (23), supplemented
with 10% heat-inactivated fetal bovine serum (Life Technologies,
Inc.).
Purification of Procyclins--
For the experiments shown in
Figs. 2-5, the procyclins (including GPEET- and EP forms) were
purified from 1011 freeze dried trypanosomes by organic
solvent extraction followed by octyl-Sepharose chromatography (Amersham
Pharmacia Biotech) (13, 15, 19). As judged by SDS-polyacrylamide gel
electrophoresis and silver staining, the procyclin-containing fractions
from the octyl-Sepharose column showed a major component with a highly polydisperse migration and an apparent molecular mass of ~45 kDa (not
shown). Sugar analysis of a pool of these fractions by gas chromatography mass-spectrometry (24) yielded a composition of Man,
Gal, GlcNAc, sialic acid, and myo-inositol of
5.2:14.8:27:4.2:1, similar to values reported previously (13, 15). Some
preparations also contained a minor component that migrated near 11 kDa
on SDS-polyacrylamide gel electrophoresis. This component was
identified as the kinetoplastid membrane protein-11, a protein known to
co-purify with procyclin preparations (25). MALDI-TOF-MS analysis
revealed this component as a broad peak with an average molecular mass of 11,070 Da (not shown).
The mass spectrometry analysis of procyclins from cloned cell lines was
performed directly from n-butanol extracts without further
purification by octyl-Sepharose chromatography. The mass spectra of
these preparations were as clean as those obtained using procyclin
purified by the standard chromatographic method (see example in Fig.
6).
Removal of the Procyclin GPI Anchors by aq.HF
Dephosphorylation--
Octyl-Sepharose purified procyclin (1-2 nmol,
based on myo-inositol content) or n-butanol
extracts from cloned cells were dephosphorylated with 50 µl (or 25 µl in the case of butanol extracts) of cold 48% aq.HF (Aldrich) for
16 h at 0 °C (19). After hydrolysis, samples were quickly
frozen in dry ice/ethanol and dried in the Speed-Vac. Samples were
resuspended in 5-10 µl of water and stored at 20 °C.
MALDI-TOF-MS--
Mass spectra were acquired in a PerSeptive
Biosystems Voyager-DE mass spectrometer calibrated with insulin,
thioredoxin, and apomyoglobin. For the analysis of native procyclin
(500 pmol; non-aq.HF-treated), samples were co-crystallized with
sinapinic acid. Polypeptides dephosphorylated with aq.HF (50 pmol)
provided better spectra using -cyano-4-hydroxycinnamic acid as the
matrix. All spectra were collected in the negative ion mode.
Analysis of N-terminal Sequences by Electrospray Ionization-Mass
Spectrometry (ESI-MS) and Tandem-Mass Spectrometry--
ESI-MS was
performed using a Finnigan LCQ atmospheric pressure ionization
quadrupole ion trap mass spectrometer (ThermoQuest Corp.). The mass
spectrometer was equipped with an X-Y-Z-positioner carriage source
(Protana A/S) and a sample loop containing a C18 microtrap cartridge
(Michrom BioResources). Samples were resuspended in 50 mM
formic acid, loaded onto the C18 microtrap cartridge, and then sprayed
into the mass spectrometer through a 50-µm (inner diameter) fused
silica needle by eluting with 50% methanol/1% acetic acid at 10 µl/min. Spray voltage was set at 1.75 kV with no sheath or auxiliary
gas flow and a capillary temperature of 200 °C. Other voltages were
set automatically by tuning on the 881 [M+2H]2+ ion of a
renin substrate tetradecapeptide standard (Sigma). Full scan and MS/MS
fragmentation data were collected in centroid mode with two microscans
during a 500-ms maximum injection time using the default automatic gain
control target number of ions. Quadruply charged ions were fragmented
with a 40% collision energy and an isolation width of 2.0 atomic mass units.
Cleavage of EP-procyclins by Mild Acid
Hydrolysis--
aq.HF-treated procyclin (50 pmol of dephosphorylated
polypeptides) was hydrolyzed with 40 mM trifluoroacetic
acid (TFA) (Pierce) at 100 °C for 15 min. After hydrolysis, the
samples were chilled in ice water and washed with 50 µl of water to
remove residual TFA. For analysis of the EP-procyclin N-terminal
sequences by ESI-MS, 4.5 nmol of native procyclin was submitted to TFA
hydrolysis as indicated above. The dried protein, in 50 µl of 0.1 M ammonium acetate, 5% n-propanol (v/v), was
loaded onto a mini-octyl-Sepharose column (~0.5 ml) previously
equilibrated in the same buffer. Whereas the C-terminal fragments as
well as the nondegraded protein bound tightly to the hydrophobic resin
through their GPI anchors, the hydrophilic N-terminal fragments were
collected in the flow-through of the column. The column was washed with
1 ml of 0.1 M ammonium acetate, 5% n-propanol
(v/v), and the collected material was pooled, dried in the Speed-Vac,
and freeze-dried twice to remove residual ammonium acetate.
Enzymatic Deglycosylation of Procyclin
Polypeptides--
aq.HF-treated procyclin (200 pmol) was
deglycosylated with 500 units of peptide
N4(N-acetyl- -glucosaminyl) asparagine amidase
F (PNGase F) (New England Biolabs) in 10 µl of 25 mM
sodium phosphate at 37 °C for 2 h. After digestion, 1 µl of
the sample was directly mixed with 1 µl of
-cyano-4-hydroxycinnamic acid and analyzed by MALDI-TOF-MS. For
analysis of procyclin N-terminal polypeptides by ESI-MS, the polypeptides obtained after mild acid hydrolysis and octyl-Sepharose chromatography (see above) were incubated with PNGase F as described above except that the buffer was 50 mM sodium phosphate and
the digestion conditions were 37 °C for 5 h. Prior to mass
spectral analysis, the deglycosylated polypeptides were desalted using a ZipTip (Millipore Corp.) containing C18 silica. Samples were eluted
as recommended by the manufacturer, dried in a Speed-Vac, and
resuspended in 50 mM formic acid before analysis.
Analysis of Phosphoryl Groups in EP-procyclin--
Procyclins
(450 pmol) were dephosphorylated (or mock treated) with 2 units of calf
intestine alkaline phosphatase (Roche Molecular Biochemicals) in 10 µl of 50 mM Tris-HCl, 0.1 mM EDTA, pH 8.5, at
37 °C for 16 h. After digestion, the samples were dried in the
Speed-Vac and incubated with 25 µl of 48% aq.HF at 0 °C for 6 h. An aliquot of the HF-treated sample (45 pmol) was submitted to mild acid hydrolysis as described above and then deglycosylated with
250 units of PNGase F (Biolabs) for 2 h at 37 °C. After each step, 10% of each sample was analyzed by MALDI-TOF-MS.
 |
RESULTS |
Characterization of Native Procyclin by Mass Spectrometry--
For
MALDI-TOF-MS analysis, we first used native procyclin purified by
organic solvent extraction and octyl-Sepharose chromatography. The
negative ion spectrum revealed a highly heterogeneous group of
[M-H] pseudomolecular ions in the range of
m/z 14,000-20,000 (average m/z, 17,400), consistent with an average mass of
17.4 kDa (not shown). A comparable spectrum was reported previously for
purified GPEET-procyclin, and the extensive heterogeneity observed is
mainly due to the polydisperse side chain of the GPI anchor (13, 19). To distinguish the different EP-procyclin species, it was first essential to remove the GPI anchors.
Characterization of the EP-procyclin Polypeptides by Mass
Spectrometry after Removal of GPI Anchors--
We removed the anchors
by treatment with cold 48% aq.HF, a reagent that cleaves the
phosphodiester bond between the anchor ethanolamine and the GPI glycan
core (26, 27). This treatment preserves most polypeptide chains with
N-glycan moieties intact and leaves the GPI ethanolamine
amide-linked to the C-terminal -carboxyl. In the case of
EP-procyclin, HF also produced minor cleavages in the protein backbone,
mainly at the mild acid-sensitive Asp-Pro bonds (see below).
The negative ion MALDI mass spectrum of HF-treated procyclins revealed
many [M-H] pseudomolecular ions in the range of
m/z 5,000-12,000 (Fig.
2A). Although the spectrum is
complex, nearly all of these species were interpretable in terms of the
well characterized procyclin gene sequences and
N-glycosylation patterns. Table
I lists the masses and assignments of the
various species detected. Two ions at m/z 11,531 (ion 1) and 10,430 (ion 3) had molecular masses for two different
glycosylated products of the EP1 gene, each also containing
one ethanolamine. According to their cDNA sequences and results
shown later in this paper, these proteins differ in both the number of
EP repeats (30 for ion 1, 25 for ion 3) and in one amino acid at
position 24 (4, 6-8) (Fig. 1B). We have designated these
ions as the products of the EP1-1 and EP1-2
genes, respectively. Another major [M-H] ion at
m/z 9,723 (ion 4) matches the calculated mass of
the glycosylated product of the EP-procyclin EP3 gene, a
protein with 22 EP repeats (5, 9) (Fig. 1B). Interestingly,
no ion corresponding to the product of the EP-procyclin EP2
gene (expected mass = 8,571, including one ethanolamine) was
observed. However, a tiny peak at m/z 8,344 (ion
10) was tentatively assigned as a product of this gene, but this
polypeptide contained only 24 EP repeats instead of the 25 predicted
from the published cDNA sequence (10). To distinguish both
EP-procyclin species, we have designated them as EP2-1 (containing 25 EP repeats) and EP2-2 (containing 24 EP repeats). As expected, the
mass of EP2-2 procyclin (ion 10) predicted that this polypeptide was
not N-glycosylated (10).

View larger version (34K):
[in this window]
[in a new window]
|
Fig. 2.
Negative ion MALDI-TOF mass spectra of
procyclin after removal of the GPI anchors. A, see text
and Table I for assignment of ions. B, aq.HF-treated
procyclin was incubated with PNGase F to remove N-glycans
and analyzed by MALDI-TOF-MS. Note the new peaks that appeared at
m/z 3,119 and 3,332, also shown in more detail in
the inset (see text for discussion of these peaks).
Asterisks indicate polypeptides missing 10 residues from the
N terminus.
|
|
For each of the full-length EP-procyclin gene products observed in the
negative ion spectrum, we also detected a corresponding ion that lacked
ten amino acids from the N terminus (AEGPEDKGLT; Fig. 1B).
Thus, the [M-H] ions at m/z
10,533 (ion 2), 9,432 (ion 5), and 8,725 (ion 8) (marked by
asterisks on Fig. 2A) represent the truncated
forms of the EP1-1, EP1-2, and EP3
gene products, respectively. These fragments varied in abundance in
different preparations, and control experiments strongly indicated that
they originate during the aq.HF treatment (see "Discussion").
Another group of lower intensity [M-H] ions in the
range of m/z 7,500-9,500 (ions 6 and 11-15;
Table I), mainly represent minor products of nonspecific cleavages from
the N termini of the products of the EP1-1,
EP1-2, and EP3 genes. Some of them are worth
discussing because they support the assignment of two types of
EP1 gene products. For instance, those ions at
m/z 8,175 (ion 12) and 8,276 (ion 11) are
consistent with a polypeptide containing Ser at position 24 as well as
25 EP repeats, which we have designated the EP1-2
polypeptide (Table I). Likewise, the ion at m/z
9,277 (ion 6) is consistent with a polypeptide containing a Gly at
position 24 as well as 30 EP repeats, expected for the EP1-1 protein.
As discussed below, we confirmed these proposed structures of the EP1-1
and EP1-2 proteins by tandem mass spectrometry. Finally, another group
of ions (ions 17, 18, 22, 23, 27, 28, and 29) derives from cleavage at
Asp-Pro sequences, the major side reaction of the HF dephosphorylation.
We will discuss the significance of these ions below, in the section on
mild acid hydrolysis.
Characterization of GPEET-procyclin Polypeptides--
We also
detected polypeptides derived from GPEET-procyclin, the product of the
GPEET gene. The ion at m/z 6,142 (ion
21) corresponded to the intact GPEET-procyclin polypeptide and that at
m/z 6,222 (ion 20) to the same polypeptide
containing one phosphate group. Presumably the other phosphates had
been removed during the aq.HF dephosphorylation. These values are
consistent with those recently reported for the same molecule (19). The
ion at m/z 5,703 (ion 25) corresponds to
nonphosphorylated GPEET-procyclin that has lost its N-terminal sequence
VIVK (Fig. 1B).
Glycosylation of the EP-procyclin Polypeptides--
The major
EP-procyclin polypeptides identified in Fig. 2A have
molecular masses consistent with its single Asn being modified by a
Hex5HexNAc2 oligosaccharide. Previous
structural analyses have proven that this glycan is
Man5GlcNAc2 (13, 14). To further confirm our
polypeptide assignments and to determine the occupancy of the
N-glycosylation sites, we deglycosylated a sample like that
in Fig. 2A with PNGase F and then analyzed the products by MALDI-TOF-MS (Fig. 2B). The major ions corresponding to the
intact polypeptide products of the EP1-1, EP1-2,
and EP3 genes are missing (ions 1, 3, and 4) as are the
corresponding ions that have lost the N-terminal decapeptide (ions 2, 5, and 8). In their place are new ions at m/z
10,314, 9,213, and 8,506, which have values corresponding to the
deglycosylated products of the EP1-1, EP1-2, and
EP3 genes, respectively, as well as ions at 9,316 m/z (EP1-1), 8,215 (EP1-2), and 7,508 (EP3),
which are the deglycosylated species with truncated N termini. In all
cases, the mass of the deglycosylated species is 1217 Da less than that
of the native species, a mass corresponding to that of a
Hex5HexNAc2 glycan. The corresponding deglycosylated species detected in Fig. 2B were present only
in very low levels in the MALDI spectrum shown in Fig. 2A,
indicating that most of the EP-procyclin polypeptides were occupied by
a single N-glycan, as predicted in a previous report (13).
Furthermore, we found no evidence of any heterogeneity in this glycan,
also in agreement with previous reports (13, 14).
Interestingly, after PNGase F incubation (Fig. 2B and
inset), two new very intense ions at
m/z 3,119 and 3,331 were detected. These ions
were identified as the deglycosylated N-terminal fragments Ala1-Asp34 (m/z 3,331)
and Ala1-Asp32 (m/z
3,119) of the EP1-1 and EP33
proteins, produced by cleavage at Asp-Pro bonds. An amplification of
the region between m/z 3,000-3,500
(inset, Fig. 2B) showed that there were two
additional ions. These were identified as the deglycosylated N-terminal
fragments Ala1-Asp34
(m/z 3,360) and
Ala1-Asp32 (m/z 3,147)
of the EP1-2 protein. As shown in Fig. 1B, the
EP1-2 and EP1-1 gene products differ in this
region only by the presence of a Gly or a Ser at position 24. The
corresponding ions in their glycosylated form (e.g.
m/z 4,577 and 4,365) were never observed in the
sample not treated with PNGase F (Fig. 2A), even when
analyzed in the positive mode (not shown).
Characterization of the C-terminal Fragments of the EP-procyclins
after Selective Mild Acid Hydrolysis of the Asp-Pro Bonds--
To
confirm the number of EP repeats, we partially hydrolyzed the procyclin
polypeptides (already aq.HF-treated) with 40 mM TFA at
100 °C for 15 min. Under these relatively mild conditions, Asp-Pro
peptide bonds (found at residues 32-35 in EP3 and EP1 procyclins) are
preferentially cleaved (28). The negative ion MALDI-TOF-MS spectrum
after mild acid hydrolysis (Fig. 3)
confirmed that cleavage occurs at these Asp-Pro sequences, generating
distinct C-terminal
fragments.4 Every
EP-procyclin molecule was cleaved at one of these sites, because no
ions in the range m/z 8,000 to 12,000 were
detected (not shown). In the range of m/z 5,000 and 7,000, three major ions were observed. These ions were identified
as the C-terminal fragments
Pro35-(Glu-Pro)22-Gly80-EtN
(m/z 5,191),
Pro35-(Glu-Pro)25-Gly86-EtN
(m/z 5,870) and
Pro35-(Glu-Pro)30-Gly96-EtN
(m/z 7,001), which derive from the
EP3, EP1-2, and EP1-1 products, respectively.
Each of these fragments is also paired with an ion
(m/z 5,403, 6,082, and 7,213) whose mass is
larger by about 212 Da (the mass of a Pro-Asp dipeptide). These
fragments derive from cleavage at the upstream Asp-Pro sequence. As
mentioned above, partial cleavage at Asp-Pro bonds was also detected in Fig. 2A, as a side reaction of the aq.HF dephosphorylation
used to remove GPI anchors. The ion at m/z 4,965 (also detected in Fig. 2A) corresponds to the C-terminal
fragment (i.e. Pro(Glu-Pro)21Gly-EtN) of an
unidentified EP-procyclin. The origin of this species is unknown
because its intensity is very low and the predicted full-length product
(adding the mass of either an EP1 or EP3 N terminus) was either
undetected or masked by other ions in Fig. 2A. However, this
C-terminal fragment could derive from an isoform of the EP3 product.

View larger version (23K):
[in this window]
[in a new window]
|
Fig. 3.
Analysis of the EP-procyclin C-terminal
domains by MALDI-TOF-MS. HF-treated procyclin was submitted to
mild acid hydrolysis with 40 mM TFA, and the products were
analyzed by MALDI-TOF-MS. The ions in the range of
m/z 4,000-5,000 correspond to nonspecific
fragmentation of the EP repeats.
|
|
Confirmation of Sequences of Procyclin N-terminal Fragments by
Electrospray Ionization-MS--
To confirm that two different
EP1 gene products were present, we conducted partial
N-terminal sequencing by tandem mass spectrometry. We subjected native
procyclin (not aq.HF-treated) to mild acid hydrolysis to cleave at the
Asp-Pro bonds. We then separated the N-terminal fragments from the
C-terminal domains (containing a GPI anchor) using octyl-Sepharose
chromatography. We collected the hydrophilic N-terminal fragments in
the flow-through of this column, deglycosylated them with PNGase F, and
then analyzed the products by ESI-MS. Analysis in the positive mode
showed several major [M+4H]4+ pseudomolecular ions (not
shown). Two major ions at m/z 788.4 and 841.4 matched the predicted values of the nonglycosylated fragments
Ala1-Asp32 and
Ala1-Asp34 from the EP1-2 protein. Likewise,
the ions at m/z 780.8 and 833.9 matched the
calculated [M+4H]4+ values for the same fragments from
EP1-1 and EP3 procyclins, respectively (not shown). Consistent with the
presence of these quadruply charged ions, we also detected a group of
ions (m/z 1,040.6, 1,050, 1,111.8, and 1,121.5)
that derive from the same species, except that they are triply charged
(not shown).
Collision-induced dissociation (CID) daughter ion spectra of the
[M+4H]4+ m/z 788.4 (Fig.
4A) and 780.8 (not shown)
parent ions, generated, in both cases, multiply charged N-terminal
(b-series) and C-terminal (y-series) daughter ions. The major daughter
ions in both spectra were the quadruply charged b ions
(b31-324+), which confirmed the
sequences Ala1-Thr31 and
Ala1-Asp32. However, the more informative
series were the triply charged b ions (b3+), because they
defined the region where the three polypeptides have different amino
acid sequences (i.e. positions 18, 24 and 25). The results
are summarized in Fig. 4B, in which the observed masses
(from the spectrum in Fig. 4A) can be compared with the predicted masses of the b3+ series for the three
EP-procyclin gene products (only N-terminal fragments). These results,
together with those obtained from MALDI-TOF-MS analyses (Fig.
2A and Table I), confirm the presence of the products of the
EP1-1, EP1-2, and EP3 genes.

View larger version (28K):
[in this window]
[in a new window]
|
Fig. 4.
CID-ESI-MS analysis of EP-procyclin N
termini. Native procyclin (not HF-treated) was submitted to mild
acid hydrolysis, and the N-terminal fragments were purified,
deglycosylated with PNGase F, and analyzed by ESI-MS. A, CID
daughter ion spectrum of the 788.4 parent ion (from EP1-2 procyclin).
b and y represent the b (N-terminal) and y
(C-terminal) series, respectively. The CID daughter ion spectrum of the
780.8 parent ion (from EP1-1 and EP3 proteins) is not shown, but it
presents a similar pattern of fragmentation. B, N-terminal
polypeptide sequences detected in the CID mass spectra. Only the
b3+ series from each polypeptide is shown.
Underlined values represent the theoretical masses
(b3+ ions) that matched the [M+3H]3+ ions
identified in the CID daughter ion spectra. Nonunderlined
values were not detected in the spectra. Amino acid residues that
differ in the three polypeptides are underlined.
|
|
Is EP-procyclin Phosphorylated?--
It is well established that
the GPEET-procyclin is highly phosphorylated on the amino acid repeats
(18-20), but the presence of this modification has not been determined
for the EP isoforms. The EP-procyclins contain several Thr or Ser
residues that could be phosphorylation sites. Consistent with
phosphorylation, we found that MS analysis of procyclins treated for
2-8 h with aq.HF showed, in addition to the phosphorylated GPEET
forms, new peaks (not detected in the MS in Fig. 2A) that
were larger by 80 Da than each EP isoform (not shown). This finding
suggested the presence of singly phosphorylated EP-procyclin species.
We then studied whether this phosphate is present in the N-terminal
domain or linked to the C-terminal ethanolamine, deriving from the GPI
anchor. We incubated native procyclin for 16 h with calf intestine
alkaline phosphatase and then treated it for 6 h with aq.HF, and
finally submitted it to mild acid hydrolysis. Analysis by MALDI-TOF-MS showed that each of the major C-terminal polypeptides
(m/z 5,191, 5,870, and 7,001) of the
EP-procyclins is partly phosphorylated, resulting in ions of
m/z 5271, 5,950, and 7,081, respectively (Fig.
5A). We also detected
phosphorylated species of the less abundant C-terminal fragments that
were cleaved at the upstream Pro-Asp bond (i.e.
m/z 5,403, 6,082, and 7,213), as well as the fragment P(EP)21G-EtN (m/z 4,965).
Because these phosphate groups had resisted hydrolysis by alkaline
phosphatase, these results indicate that they were originally present
in the native molecules as phosphodiesters. Furthermore, subsequent
deglycosylation of the same sample4 showed that none of the
N-terminal fragments was phosphorylated (Fig. 5B). Taken
together, these results provide strong evidence that in contrast to
GPEET-procyclin, the EP-procyclins are not phosphorylated. The residual
phosphate groups detected by mass spectrometry after short HF treatment
must derive from the phosphodiester bond originally present between the
C-terminal ethanolamine and the GPI glycan core.

View larger version (29K):
[in this window]
[in a new window]
|
Fig. 5.
Location of the phosphoryl group on
EP-procyclin polypeptides. Native procyclin was dephosphorylated
with alkaline phosphatase, then digested for 6 h with HF, and
finally submitted to mild acid hydrolysis. The products were then
analyzed by negative ion MALDI-TOF-MS. A, spectrum of the
EP-procyclin C termini. P in a circle,
indicates the phosphorylated C-terminal species. The ions between 3,500 and 4,000 m/z correspond to the ladder of EP
repeats previously described in Fig. 3. B, analysis of the N
termini after deglycosylation. Note the presence of minor truncated
N-terminal fragments (between 2,000-3,000 m/z),
which are consistent with most of the C-terminal fragments identified
in Fig. 2A. Sequences are shown above each pair of peaks.
|
|
Stability of Expression of the Procyclin Repertoire--
The
parasites used for this study had been stored at New York University
since 1988, soon after they had been transformed from a cloned
bloodstream form (strain 118). They had been cultured only about 6 weeks before the isolation of procyclins used in the experiments shown
in Figs. 2-5. To determine whether the procyclin repertoire was
identical in all cells in the population, we examined 10 clones from
this population obtained at New York University and 1 additional clone
obtained at Johns Hopkins. All 11 clones had virtually identical
procyclin compositions (Fig. 6). They also resembled that of the 1988 strain (Fig. 2A), except
that we could barely detect GPEET-procyclin species and the amount of
EP3 procyclin was slightly more abundant (Fig. 6). These results indicate that there is little variation from cell to cell in the original population. We also studied whether or not the EP-procyclin repertoire changed with time in culture. In cells from cultures passaged for 2 years at New York University or 6 months at Johns Hopkins, we found that the repertoire was nearly identical to that in
the 1988 strain. However, in both cultures the GPEET-procyclin had
virtually disappeared (not shown).

View larger version (22K):
[in this window]
[in a new window]
|
Fig. 6.
Negative ion MALDI-TOF mass spectrum of
procyclin from a clonal cell line. Procyclin from clone
D58H-B7-11 (22) was extracted with organic solvent and not further
purified by octyl-Sepharose chromatography. The GPI anchors were
removed by HF treatment. See Table I for assignments of ions.
Asterisks indicate polypeptides missing 10 residues from the
N terminus.
|
|
 |
DISCUSSION |
Since the discovery of T. brucei procyclin proteins (3,
29) and their encoding genes (4, 5, 11), there has been extensive study
of the expression and regulation of the genes, their GPI anchors, and
their N-glycan (13-15, 18, 19). However, there has been
little characterization of the different procyclin polypeptides
expressed on the cell surface. Of the various polypeptides predicted
from the gene sequences, only an unfractionated mixture of the
EP-procyclin species (3, 15, 29, 30) and, more recently,
GPEET-procyclin (13, 14, 18-20) have been demonstrated to exist as
proteins. The identification of individual EP-procyclin polypeptides
has been extremely difficult because they have very similar sequences
and therefore are not resolved by SDS-polyacrylamide gel
electrophoresis or other fractionation techniques, even after removal
of their highly heterogeneous GPI anchors. Fractionation is made even
more difficult because the proteins are almost impossible to detect by
conventional protein stains or by absorption at 280 nm. It is, however,
possible to detect the unfractionated EP-procyclin species and
GPEET-procyclin using specific monoclonal antibodies (3, 14,
20).
Using MALDI-TOF-MS we have been successful in identifying all of the
procyclin species (both the EP and GPEET forms) in a clone of T. brucei strain 427. We used HF treatment to remove the GPI anchors
and then, in a key reaction, used mild acid hydrolysis to cleave
selectively the products of the EP3, EP1-2, and
EP1-1 genes at Asp-Pro sequences. We found that the 427 clone expresses the products of three genes encoding EP forms
(EP3, EP1-2, and EP1-1) as well as the
product of the gene encoding GPEET-procyclin (GPEET). Surprisingly, we
detected only a trace of EP-procyclin encoded by one of the
EP2 genes, the EP2-2.
We detected several fragments derived from the full-length
polypeptides. For all EP-procyclin species, we found fragments missing
10 residues from the N termini. These fragments varied in abundance in
different preparations, and control experiments indicated that they
probably formed during the aq.HF treatment by cleavage at the
Thr10-Lys11 bond. Consistent with this
hypothesis, we detected no N-terminal fragment lacking this region in
the ESI-mass spectrum, because this preparation had not been
aq.HF-treated (not shown). In the case of GPEET-procyclin, we found
polypeptides missing four residues from the N terminus. This fragment
had been detected previously by MS (19) and also by Edman degradation
(13, 14, 18). Because the protein used for Edman sequencing was intact,
this fragment is not dependent on HF treatment and is probably present in the cell.
In agreement with previous results (18-20), we detected
phosphorylation of GPEET-procyclin. Previous studies had revealed that six out of seven threonine residues in this protein are phosphorylated (19), but we detected only a single phosphate, presumably because of
the longer duration of our aq.HF treatment (16 h compared to 8 h
in the previous study). We did not detect phosphorylation of
EP-procyclins in the mass spectra presented in this paper. We did
detect singly phosphorylated EP-procyclin molecules if the time of
aq.HF treatment was reduced to 2-8 h (not shown), but that phosphate
is linked to the C-terminal ethanolamine and derives from the GPI
anchor (Fig. 5). Furthermore, we detected no phosphoamino acids in the
N-terminal domain of EP-procyclins by both ESI-MS (not shown) and
CID-ESI-MS analysis (Fig. 4). This preparation had not been subjected
to HF treatment and had been treated only with mild acid to cleave the
protein at Asp-Pro sequences (conditions in which phosphomonoester
groups should remain attached to proteins). Thus, we conclude that the
EP-procyclins are not phosphorylated on the polypeptide chains.
The MS analysis was informative about the glycosylation state of
EP-procyclin. As mentioned above, the major EP-procyclin gene products
that we detected (i.e. EP3, EP1-2, and EP1-1) contain a
single N-glycosylation site at Asn29. Our
results confirmed that this site is modified by a homogeneous Hex5HexNAc2 glycan, previously shown to be
Man5GlcNAc2 (13, 14). Because only trace
deglycosylated EP-procyclin species were detected in the absence of
PNGase F treatment, we concluded that the occupancy of this asparagine
is greater than 90%. It is interesting that this parasite expresses
little (if any) of a variant of the EP-procyclin encoded by the
EP2 gene, which is the only nonglycosylated EP-procyclin
product that also lacks Asp-Pro bonds (10) (Fig. 1B). It is
possible that this protein is not regularly expressed in parasites
cultured in vitro but that instead it has a programmed
expression during parasite development in the insect vector. Another
related possibility is that the EP2 gene is active only
under some conditions, and in fact we have found that a T. brucei mutant (ConA 4-1) selected by resistance to killing by
concanavalin A in in vitro culture (14) expresses another
variant of the EP2 gene product (the EP2-3 protein) as its
major procyclin species.5
One potential limitation of the MALDI-TOF-MS method in evaluating the
procyclin repertoire is that different components in the mixture may
vary in sensitivity of detection. For example, we never detected by
MALDI-TOF-MS the N-terminal fragments (resulting from the cleavage at
the Asp-Pro bonds) of the EP3, EP1-2, and EP1-1 proteins, until they
were deglycosylated with PNGase F (Fig. 2, compare A and
B). It is not clear why these species were not detected, but
the N-glycan may have interfered either with
co-crystallization with the matrix or with their detection in the
negative mode. Nevertheless, most procyclin species have such closely
related structures that they are likely to be detected with similar
sensitivities. Using Edman N-terminal sequencing analysis of total
procyclin purified from the same clone, we estimated that this
preparation contained ~21% GPEET-procyclin (14). Given the
difficulty in analyzing mixtures of polypeptides by Edman sequencing,
this result is in reasonable agreement with that presented in Fig.
2A.
These studies provide detailed information about the expression of
procyclin genes. It is striking that one gene in each locus seems to be
expressed, at the protein level, at a much higher level than the other.
For example, although the GPEET and EP3 gene
products are encoded in the same locus, very little of GPEET-procyclin compared with EP3 procyclin was detected (Figs. 2A and 6).
Likewise, the EP2 and the EP1 genes are located
in the same locus, but only barely detectable amounts of EP2 procyclin
were observed. Thus, given the polycistronic nature of procyclin
transcription, these findings suggest that expression of the
EP2 and the GPEET genes is regulated by
post-transcriptional mechanisms. Specific domains at the
3'-untranslated region of procyclin mRNA have been identified as
regions that modulate RNA stability and translation in both bloodstream
and procyclic forms (31-33). Alternatively, expression of these
proteins could also be regulated by undefined translational or
post-translational mechanisms. In any case, regulation of procyclin expression is a complex process that occurs at different levels (12,
34). Comparison of protein levels, as described in this paper, with
mRNA levels should help to clarify these regulatory mechanisms.
It is likely that the two distinct EP1-procyclins, EP1-1 and EP1-2, are
allelic copies of the same gene. An alternative possibility, that they
derive from different cells in the population, is ruled out by the fact
that this population of procyclic cells was derived from a cloned
bloodstream form and therefore should be clonal themselves. In
addition, our finding that 11 clones derived from this population all
had identical repertoires of EP-procyclin provides further evidence
that these cells express both forms of the EP1 gene. Both
EP1 proteins had already been identified at the DNA sequence level but
from different parasite clones (4, 6-8), and their allelic variability
has been previously demonstrated by Southern blot analysis (35). It is
also reasonable to conclude that the allelic copies of the
EP2 genes also differ in sequence, because the
EP2 gene sequence predicted 25 EP repeats (10), whereas the
candidate EP2 protein that we detected (ion 10 in Table I) had 24 EP
repeats. Likewise, the presence of a C-terminal fragment containing 21 EP repeats (Figs. 2A and 3) might suggest the presence of
another EP3 gene product. Allelic variability has also been
documented for others T. brucei genes, for example those for
RNA polymerase II (36).
We were surprised to find that clones derived from the population of
1988 cells had lost almost all expression of GPEET-procyclin, although
their EP-procyclin repertoire was similar to that of the parent cells.
This finding was unexpected in that others had reported that over time,
expression had switched from low levels of GPEET-procyclin to high
levels (13, 18). In fact, in our own laboratory on a previous occasion,
we had observed increasing levels of GPEET-procyclin after a few months
of culture. This variability in switching of expression of different
procyclin genes implies that some uncontrolled factor in culturing
conditions influences procyclin expression. For example, variation in
serum, present in the culture medium, could be responsible. The latter may be relevant in the expression of different procyclin proteins during development in the insect vector, because all protein components in serum should be gradually degraded during the first few days of
infection of the vector. Furthermore, such a switch in the expression
of procyclin genes could modulate the interaction of the parasite with
the insect vector. We are conducting further studies to determine
whether serum or other factors are responsible for this change in
procyclin expression.
In summary, using a new methodology that combines mild acid hydrolysis
and mass spectrometry, we were able distinguish, with high accuracy,
the whole repertoire of procyclin polypeptides expressed by several
procyclic T. brucei clones. Using this methodology we have
obtained new information about procyclin expression and its
post-translational modifications. Because the mass spectrometry analyses can be performed directly using n-butanol extracted
molecules (without further purification by hydrophobic interaction
chromatography) and from as few as 105 cell
equivalents,6 this
methodology could aid in the determination of structure-function relationships of T. brucei surface glycoproteins in the
insect vector.
 |
ACKNOWLEDGEMENTS |
We thank Terry Pearson, Kim Paul, Yasu
Morita, Isabel Roditi, Jim Morris, David Jiang, and Peter Butikofer for
helpful discussions and critical reading of the manuscript. We also
thank Isabel Roditi and Christine Clayton for helpful suggestions on
the procyclin nomenclature.
 |
FOOTNOTES |
*
This work was supported by National Institutes of Health
Grants AI21334 (to P. T. E.) and AI28953 (to M. S.-G. L.) and by Wellcome Trust Program Grant 054491 (to M. A. J. F.).The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in
accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
§
Supported in part by a postdoctoral Fellowship from Consejo
Nacional de Investigaciones Científicas y
Tecnológicas (Venezuela). To whom correspondence should be
addressed. Tel.: 410-955-3458; Fax: 410-955-7810; E-mail:
aacostas@welchlink.welch.jhu. edu.
¶
Supported by the American Health Assistance Foundation.

Burroughs Wellcome Fund New Investigator in Molecular Parasitology.
2
These proteins have also been called procyclic
acidic repetitive proteins (PARPs), but a new standard nomenclature for
genes and proteins now uses the term procyclin (37).
3
The calculated mass of the N-terminal fragment
of EP3 procyclin is only 2 Da smaller than that of the EP1-1 protein,
so we assigned these peaks as containing fragments from both gene products.
4
The N-terminal fragments are not seen in the
negative ion mode unless the N-glycan is removed.
5
A. Acosta-Serrano, R. N. Cole, A. Mehlert,
J. D. Bangs, M. A. Ferguson, and P. T. Englund,
manuscript in preparation.
6
A. Acosta-Serrano and P. T. Englund,
unpublished observation.
 |
ABBREVIATIONS |
The abbreviations used are:
VSG, variant surface
glycoprotein;
EP-procyclin, a form of procyclin rich in Glu-Pro
repeats;
GPEET-procyclin, a form of procyclin rich in
Gly-Pro-Glu-Glu-Thr repeats;
GPI, glycosyl phophatidylinositol;
aq.HF, 48% aqueous hydrofluoric acid;
MS, mass spectrometry;
MALDI-TOF-MS, matrix-assisted laser desorption ionization time-of-flight MS;
TFA, trifluoroacetic acid;
ESI-MS, electrospray ionization-mass
spectrometry;
EtN, ethanolamine;
PNGase F, peptide
N4(N-acetyl- -glucosaminyl) asparagine amidase
F;
CID, collision-induced dissociation.
 |
REFERENCES |
| 1.
|
Vickerman, K.
(1969)
J. Cell Sci.
5,
163-193[Abstract/Free Full Text]
|
| 2.
|
Cross, G. A. M.
(1975)
Parasitology
71,
393-417[Medline]
[Order article via Infotrieve]
|
| 3.
|
Richardson, J. P.,
Beecroft, R. P.,
Tolson, D. L.,
Liu, M. K.,
and Pearson, T. W.
(1988)
Mol. Biochem. Parasitol.
31,
203-216[CrossRef][Medline]
[Order article via Infotrieve]
|
| 4.
|
Mowatt, M. R.,
and Clayton, C. E.
(1987)
Mol. Cell. Biol.
7,
2838-2844[Abstract/Free Full Text]
|
| 5.
|
Roditi, I.,
Carrington, M.,
and Turner, M.
(1987)
Nature
325,
272-274[CrossRef][Medline]
[Order article via Infotrieve]
|
| 6.
|
Rudenko, G.,
Le Blancq, S.,
Smith, J.,
Lee, M. G.,
Rattray, A.,
and Van der Ploeg, L. H.
(1990)
Mol. Cell. Biol.
10,
3492-3504[Abstract/Free Full Text]
|
| 7.
|
Dorn, P. L.,
Aman, R. A.,
and Boothroyd, J. C.
(1991)
Mol. Biochem. Parasitol.
44,
133-139[CrossRef][Medline]
[Order article via Infotrieve]
|
| 8.
|
Jackson, D. G.,
Smith, D. K.,
Luo, C.,
and Elliott, J. F.
(1993)
J. Biol. Chem.
268,
1894-1900[Abstract/Free Full Text]
|
| 9.
|
Clayton, C. E.,
Fueri, J. P.,
Itzhaki, J. E.,
Bellofatto, V.,
Sherman, D. R.,
Wisdom, G. S.,
Vijayasarathy, S.,
and Mowatt, M. R.
(1990)
Mol. Cell. Biol.
10,
3036-3047[Abstract/Free Full Text]
|
| 10.
|
Rudenko, G.,
Bishop, D.,
Gottesdiener, K.,
and Van der Ploeg, L. H.
(1989)
EMBO J.
8,
4259-4263[Medline]
[Order article via Infotrieve]
|
| 11.
|
Mowatt, M. R.,
Wisdom, G. S.,
and Clayton, C. E.
(1989)
Mol. Cell. Biol.
9,
1332-1335[Abstract/Free Full Text]
|
| 12.
|
Roditi, I.,
Furger, A.,
Ruepp, S.,
Schurch, N.,
and Butikofer, P.
(1998)
Mol. Biochem. Parasitol.
91,
117-130[CrossRef][Medline]
[Order article via Infotrieve]
|
| 13.
|
Treumann, A.,
Zitzmann, N.,
Hulsmeier, A.,
Prescott, A. R.,
Almond, A.,
Sheehan, J.,
and Ferguson, M. A.
(1997)
J. Mol. Biol.
269,
529-547[CrossRef][Medline]
[Order article via Infotrieve]
|
| 14.
|
Hwa, K. Y.,
Acosta-Serrano, A.,
Khoo, K. H.,
Pearson, T.,
and Englund, P. T.
(1999)
Glycobiology
9,
181-190[Abstract/Free Full Text]
|
| 15.
|
Ferguson, M. A. J.,
Murray, P.,
Rutherford, H.,
and McConville, M. J.
(1993)
Biochem. J.
291,
51-55
|
| 16.
|
Pontes de Carvalho, L. C.,
Tomlinson, S.,
Vandekerckhove, F.,
Bienen, E. J.,
Clarkson, A. B.,
Jiang, M.-S.,
Hart, G. W.,
and Nussenzweig, V.
(1993)
J. Exp. Med.
177,
465-474[Abstract/Free Full Text]
|
| 17.
|
Engstler, M.,
Reuter, G.,
and Schauer, R.
(1993)
Mol. Biochem. Parasitol.
61,
1-13[CrossRef][Medline]
[Order article via Infotrieve]
|
| 18.
|
Butikofer, P.,
Ruepp, S.,
Boschung, M.,
and Roditi, I.
(1997)
Biochem. J.
326,
415-423
|
| 19.
|
Mehlert, A.,
Treumann, A.,
and Ferguson, M. A.
(1999)
Mol. Biochem. Parasitol.
98,
291-296[CrossRef][Medline]
[Order article via Infotrieve]
|
| 20.
|
Butikofer, P.,
Vassella, E.,
Ruepp, S.,
Boschung, M.,
Civenni, G.,
Seebeck, T.,
Hemphill, A.,
Mookherjee, N.,
Pearson, T. W.,
and Roditi, I.
(1999)
J. Cell Sci.
112,
1785-1795[Abstract]
|
| 21.
|
Ruepp, S.,
Furger, A.,
Kurath, U.,
Renggli, C. K.,
Hemphill, A.,
Brun, R.,
and Roditi, I.
(1997)
J. Cell Biol.
137,
1369-1379[Abstract/Free Full Text]
|
| 22.
|
Lee, M. G.
(1996)
Mol. Cell. Biol.
16,
1220-1230[Abstract]
|
| 23.
|
Brun, R.,
and Shonenberger, M.
(1979)
Acta Tropica
36,
289-292[Medline]
[Order article via Infotrieve]
|
| 24.
|
Ferguson, M. A. J.
(1993)
in
Glycobiology: A Practical Approach
(Fukuda, M.
, and Kobata, A., eds)
, pp. 349-383, IRL Press, Oxford
|
| 25.
|
Stebeck, C. E.,
Beecroft, R. P.,
Singh, B. N.,
Jardim, A.,
Olafson, R. W.,
Tuckey, C.,
Prenevost, K. D.,
and Pearson, T. W.
(1995)
Mol. Biochem. Parasitol.
71,
1-13[CrossRef][Medline]
[Order article via Infotrieve]
|
| 26.
|
Ferguson, M. A. J.,
Homans, S. W.,
Dwek, R. A.,
and Rademacher, T. W.
(1988)
Science
239,
753-759[Abstract/Free Full Text]
|
| 27.
|
Butikofer, P.,
Boschung, M.,
and Menon, A. K.
(1995)
Anal. Biochem.
229,
125-132[CrossRef][Medline]
[Order article via Infotrieve]
|
| 28.
|
Inglis, A. S.
(1983)
Methods Enzymol.
91,
324-332[Medline]
[Order article via Infotrieve]
|
| 29.
|
Clayton, C. E.,
and Mowatt, M. R.
(1989)
J. Biol. Chem.
264,
15088-15093[Abstract/Free Full Text]
|
| 30.
|
Field, M. C.,
Menon, A. K.,
and Cross, G. A. M.
(1991)
EMBO J.
10,
2731-2739[Medline]
[Order article via Infotrieve]
|
| 31.
|
Schurch, N.,
Furger, A.,
Kurath, U.,
and Roditi, I.
(1997)
Mol. Biochem. Parasitol.
89,
109-121[CrossRef][Medline]
[Order article via Infotrieve]
|
| 32.
|
Furger, A.,
Schurch, N.,
Kurath, U.,
and Roditi, I.
(1997)
Mol. Cell. Biol.
17,
4372-4380[Abstract]
|
| 33.
|
Wilson, K.,
Uyetake, L.,
and Boothroyd, J.
(1999)
Exp. Parasitol.
91,
222-230[CrossRef][Medline]
[Order article via Infotrieve]
|
| 34.
|
Hotz, H. R.,
Biebinger, S.,
Flaspohler, J.,
and Clayton, C.
(1998)
Mol. Biochem. Parasitol.
91,
131-143[CrossRef][Medline]
[Order article via Infotrieve]
|
| 35.
|
Mowatt, M. R.,
and Clayton, C. E.
(1988)
Mol. Cell. Biol.
8,
4055-4062[Abstract/Free Full Text]
|
| 36.
|
Chung, H. M.,
Lee, M. G.,
Dietrich, P.,
Huang, J.,
and Van der Ploeg, L. H.
(1993)
Mol. Cell. Biol.
13,
3734-3743[Abstract/Free Full Text]
|
| 37.
| Roditi, I., and Clayton, C. (1999) Mol. Biochem. Parasitol.,
in
press
|
Copyright © 1999 by The American Society for Biochemistry and Molecular Biology, Inc.

CiteULike Complore Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
S. Manthri, M L. S Guther, L. Izquierdo, A. Acosta-Serrano, and M. A J Ferguson
Deletion of the TbALG3 gene demonstrates site-specific N-glycosylation and N-glycan processing in Trypanosoma brucei
Glycobiology,
May 1, 2008;
18(5):
367 - 383.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. Landeira and M. Navarro
Nuclear repositioning of the VSG promoter during developmental silencing in Trypanosoma brucei
J. Cell Biol.,
January 16, 2007;
176(2):
133 - 139.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. L. S. Guther, S. Lee, L. Tetley, A. Acosta-Serrano, and M. A.J. Ferguson
GPI-anchored Proteins and Free GPI Glycolipids of Procyclic Form Trypanosoma brucei Are Nonessential for Growth, Are Required for Colonization of the Tsetse Fly, and Are Not the Only Components of the Surface Coat
Mol. Biol. Cell,
December 1, 2006;
17(12):
5265 - 5274.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Utz, I. Roditi, C. Kunz Renggli, I. C. Almeida, A. Acosta-Serrano, and P. Butikofer
Trypanosoma congolense Procyclins: Unmasking Cryptic Major Surface Glycoproteins in Procyclic Forms.
Eukaryot. Cell,
August 1, 2006;
5(8):
1430 - 1440.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. R. Roper, M. L. S. Guther, J. I. MacRae, A. R. Prescott, I. Hallyburton, A. Acosta-Serrano, and M. A. J. Ferguson
The Suppression of Galactose Metabolism in Procylic Form Trypanosoma brucei Causes Cessation of Cell Growth and Alters Procyclin Glycoprotein Structure and Copy Number
J. Biol. Chem.,
May 20, 2005;
280(20):
19728 - 19736.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Leal, A. Acosta-Serrano, J. Morris, and G. A. M. Cross
Transposon Mutagenesis of Trypanosoma brucei Identifies Glycosylation Mutants Resistant to Concanavalin A
J. Biol. Chem.,
July 9, 2004;
279(28):
28979 - 28988.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. Nagamune, A. Acosta-Serrano, H. Uemura, R. Brun, C. Kunz-Renggli, Y. Maeda, M. A.J. Ferguson, and T. Kinoshita
Surface Sialic Acids Taken from the Host Allow Trypanosome Survival in Tsetse Fly Vectors
J. Exp. Med.,
May 17, 2004;
199(10):
1445 - 1450.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Acosta-Serrano, J. O'Rear, G. Quellhorst, S. H. Lee, K.-Y. Hwa, S. S. Krag, and P. T. Englund
Defects in the N-Linked Oligosaccharide Biosynthetic Pathway in a Trypanosoma brucei Glycosylation Mutant
Eukaryot. Cell,
April 1, 2004;
3(2):
255 - 263.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L. M. Thomson, D. J. Lamont, A. Mehlert, J. D. Barry, and M. A. J. Ferguson
Partial Structure of Glutamic Acid and Alanine-rich Protein, a Major Surface Glycoprotein of the Insect Stages of Trypanosoma congolense
J. Biol. Chem.,
December 6, 2002;
277(50):
48899 - 48904.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Acosta-Serrano, E. Vassella, M. Liniger, C. K. Renggli, R. Brun, I. Roditi, and P. T. Englund
The surface coat of procyclic Trypanosoma brucei: Programmed expression and proteolytic cleavage of procyclin in the tsetse fly
PNAS,
February 1, 2001;
(2001)
41611698.
[Abstract]
[Full Text]
|
 |
|

|
 |

|
 |
 
E. Vassella, J. V. Den Abbeele, P. Bütikofer, C. K. Renggli, A. Furger, R. Brun, and I. Roditi
A major surface glycoprotein of Trypanosoma brucei is expressed transiently during development and can be regulated post-transcriptionally by glycerol or hypoxia
Genes & Dev.,
March 1, 2000;
14(5):
615 - 626.
[Abstract]
[Full Text]
|
 |
|

|
 |

|
 |
 
A. Acosta-Serrano, E. Vassella, M. Liniger, C. K. Renggli, R. Brun, I. Roditi, and P. T. Englund
The surface coat of procyclic Trypanosoma brucei: Programmed expression and proteolytic cleavage of procyclin in the tsetse fly
PNAS,
February 13, 2001;
98(4):
1513 - 1518.
[Abstract]
[Full Text]
[PDF]
|
 |
|
Copyright © 1999 by the American Society for Biochemistry and Molecular Biology.
|
Advertisement
Advertisement
|